AKBA

Equity

Akebia Therapeutics, Inc.

Health Care · Drug Manufacturers - Specialty & Generic

$1.31

+1.31 (+0.00%)

Open

N/A

Day Range

$1.26 - $1.34

52W Range

$1.14 - $4.08

Volume

7M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Akebia Therapeutics Inc (AKBA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

GuruFocus.com 1 day ago

Akebia (AKBA) Q4 2025 Earnings Call Transcript

Motley Fool 1 day ago

Akebia Therapeutics Q4 Earnings Call Highlights

MarketBeat 1 day ago

Akebia Therapeutics: Q4 Earnings Snapshot

Associated Press Finance 1 day ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

GlobeNewswire 1 day ago

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ABCL AbCellera Biologics Inc. $3.61 N/A - +0.00%
ABUS Arbutus Biopharma Corporation $4.66 N/A - +0.00%
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
AHCO AdaptHealth Corp. $9.15 N/A - +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%
ACAD ACADIA Pharmaceuticals Inc. $24.56 N/A - +0.00%
A Agilent Technologies, Inc. $121.38 N/A 0.82% +0.00%
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

www.akebia.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Analysis Tools

Sign in for analysis tools

Share